Lin Liu1, David Nardo, Eric Li, Gary P Wang. 1. aDivision of Infectious Diseases and Global Medicine, Department of Medicine bDepartment of Pharmacology, University of Florida College of Medicine cNorth Florida/South Georgia Veterans Health System, Gainesville, Florida, USA.
Abstract
OBJECTIVES: CD4 T-cell depletion from HIV infection leads to a global decline in anti-hepatitis C virus (HCV) envelope neutralizing antibody (nAb) response, which may play a role in accelerating liver fibrosis. An increase in anti-HCV nAb titers has been reported during antiretroviral therapy (ART) but its impact on HCV remains poorly understood. The objective of this study is to determine the effects of ART on long-term HCV evolution. DESIGN AND METHODS: We examined HCV quasispecies structure and long-term evolution in HIV/HCV coinfected patients with ART-induced CD4 T-cell recovery, and compared with patients with CD4 T-cell depletion from delayed ART. We applied a single-variant sequencing (SVS) method to construct authentic viral quasispecies and compared sequence evolution in HCV envelope, the primary target for humoral immune responses, and NS3, a target for cellular immunity, between the two cohorts. RESULTS: The SVS method corrected biases known to skew the proportions of viral variants, revealing authentic HCV quasispeices structures. We observed higher rates of HCV envelope sequence evolution in patients with ART-induced CD4 T-cell recovery, compared with patients with CD4 T-cell depletion from delayed ART (P = 0.03). Evolutionary rates for NS3 were considerably lower than the rates for envelope (P < 0.01), with no significant difference observed between the two groups. CONCLUSION: ART-induced CD4 T-cell recovery results in rapid sequence evolution in HCV envelope, but not in NS3. These results suggest that suppressive ART disproportionally enhances HCV-specific humoral responses more than cellular responses, resulting in rapid sequence evolution in HCV envelope but not NS3.
OBJECTIVES:CD4 T-cell depletion from HIV infection leads to a global decline in anti-hepatitis C virus (HCV) envelope neutralizing antibody (nAb) response, which may play a role in accelerating liver fibrosis. An increase in anti-HCV nAb titers has been reported during antiretroviral therapy (ART) but its impact on HCV remains poorly understood. The objective of this study is to determine the effects of ART on long-term HCV evolution. DESIGN AND METHODS: We examined HCV quasispecies structure and long-term evolution in HIV/HCV coinfectedpatients with ART-induced CD4 T-cell recovery, and compared with patients with CD4 T-cell depletion from delayed ART. We applied a single-variant sequencing (SVS) method to construct authentic viral quasispecies and compared sequence evolution in HCV envelope, the primary target for humoral immune responses, and NS3, a target for cellular immunity, between the two cohorts. RESULTS: The SVS method corrected biases known to skew the proportions of viral variants, revealing authentic HCV quasispeices structures. We observed higher rates of HCV envelope sequence evolution in patients with ART-induced CD4 T-cell recovery, compared with patients with CD4 T-cell depletion from delayed ART (P = 0.03). Evolutionary rates for NS3 were considerably lower than the rates for envelope (P < 0.01), with no significant difference observed between the two groups. CONCLUSION: ART-induced CD4 T-cell recovery results in rapid sequence evolution in HCV envelope, but not in NS3. These results suggest that suppressive ART disproportionally enhances HCV-specific humoral responses more than cellular responses, resulting in rapid sequence evolution in HCV envelope but not NS3.
Authors: Alleluiah Rutebemberwa; Stuart C Ray; Jacquie Astemborski; Jordana Levine; Lin Liu; Kimberly A Dowd; Shalyn Clute; Changyu Wang; Alan Korman; Alessandro Sette; John Sidney; Drew M Pardoll; Andrea L Cox Journal: J Immunol Date: 2008-12-15 Impact factor: 5.422
Authors: Justin R Bailey; Kimberly A Dowd; Anna E Snider; William O Osburn; Shruti H Mehta; Gregory D Kirk; David L Thomas; Stuart C Ray Journal: J Infect Dis Date: 2015-03-09 Impact factor: 5.226
Authors: Xiao Tong; Stephane Bogen; Robert Chase; V Girijavallabhan; Zhuyan Guo; F George Njoroge; Andrew Prongay; Anil Saksena; Angela Skelton; Ellen Xia; Robert Ralston Journal: Antiviral Res Date: 2007-12-28 Impact factor: 5.970
Authors: Simone Susser; Christoph Welsch; Yalan Wang; Markus Zettler; Francisco S Domingues; Ursula Karey; Eric Hughes; Robert Ralston; Xiao Tong; Eva Herrmann; Stefan Zeuzem; Christoph Sarrazin Journal: Hepatology Date: 2009-12 Impact factor: 17.425
Authors: Mansun Law; Toshiaki Maruyama; Jamie Lewis; Erick Giang; Alexander W Tarr; Zania Stamataki; Pablo Gastaminza; Francis V Chisari; Ian M Jones; Robert I Fox; Jonathan K Ball; Jane A McKeating; Norman M Kneteman; Dennis R Burton Journal: Nat Med Date: 2007-12-06 Impact factor: 53.440
Authors: Doug J Bartels; Yi Zhou; Eileen Z Zhang; Michelle Marcial; Randal A Byrn; Thomas Pfeiffer; Ann M Tigges; Bambang S Adiwijaya; Chao Lin; Ann D Kwong; Tara L Kieffer Journal: J Infect Dis Date: 2008-09-15 Impact factor: 5.226
Authors: Thomas von Hahn; Joo Chun Yoon; Harvey Alter; Charles M Rice; Barbara Rehermann; Peter Balfe; Jane A McKeating Journal: Gastroenterology Date: 2006-12-03 Impact factor: 22.682
Authors: Ashley N Brown; Lin Liu; Jaime L Rodriquez; Lisa Zhao; Layla Schuster; Eric Li; Gary P Wang; Michael N Neely; Walter Yamada; George L Drusano Journal: Sci Rep Date: 2017-10-31 Impact factor: 4.379